Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZG2001
- Development stage
- Phase 2
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ZG2001 is a novel small molecule inhibitor developed by Suzhou Zelgen Biopharmaceuticals for the treatment of advanced solid tumors harboring KRAS mutations. The drug specifically targets both KRAS and SOS1 proteins, which are key components in cell signaling pathways that regulate cell growth and division. By inhibiting these proteins, ZG2001 aims to disrupt abnormal signaling caused by KRAS mutations—a common driver in various cancers such as non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The drug is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors who have progressed on or are intolerant to standard therapies[1][3][5][8].
- Other names
- ZG 2001ZG2001ZG-2001
02
Targets
SOS1 (Son of sevenless homolog 1)KRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on ZG2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZG2001.